Case Report: Resetting the Humoral Immune Response by Targeting Plasma Cells With Daratumumab in Anti-Phospholipid Syndrome

INTRODUCTION: Monoclonal antibodies (mAb) targeting plasma cells are malignant gammopathy designed and approved therapies. In recent years, these antibodies have also been increasingly introduced for non-malignant conditions such as autoimmune-mediated diseases. The Anti-Phospholipid Syndrome (APS)...

Descripción completa

Detalles Bibliográficos
Autores principales: Pleguezuelo, Daniel E., Díaz-Simón, Raquel, Cabrera-Marante, Oscar, Lalueza, Antonio, Paz-Artal, Estela, Lumbreras, Carlos, Serrano Hernández, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8072150/
https://www.ncbi.nlm.nih.gov/pubmed/33912194
http://dx.doi.org/10.3389/fimmu.2021.667515

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8072150/
https://www.ncbi.nlm.nih.gov/pubmed/33912194
http://dx.doi.org/10.3389/fimmu.2021.667515

Ejemplares similares